Brief: Alzamend Neuro Announces Completion Of Clinical Portion Of Phase Iia Multiple Ascending Dose Clinical Trial For Al001 Treatment Of Dementia Related To Alzheimer’S
22/03/2023 12:11
March 22 (Reuters) - Alzamend Neuro Inc ALZN.O :
* ALZAMEND NEURO ANNOUNCES COMPLETION OF CLINICAL PORTION OF
PHASE
IIA MULTIPLE ASCENDING DOSE CLINICAL TRIAL FOR AL001 TREATMENT
OF DEMENTIA RELATED TO ALZHEIMER’S
* ALZAMEND NEURO INC - TOPLINE DATA EXPECTED IN JUNE 2023
Source text for Eikon: ID:nBw7rpdR5a
Further company coverage: ALZN.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview